Pacira BioSciences, Inc. (PCRX) Q1 2026 Earnings
Pacira BioSciences, Inc. reported Q1 2026 revenue of $177.4M (+5.0% YoY), beat analyst consensus of $171.8M by $5.6M. Diluted EPS came in at $0.60 (-3.2% YoY), missed the $0.61 consensus by $0.01.
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about Pacira BioSciences, Inc.'s Q1 2026 earnings report.
Pacira BioSciences, Inc. (PCRX) reported Q1 2026 earnings on April 30, 2026 after market close.
Pacira BioSciences, Inc. reported revenue of $177.4M and diluted EPS of $0.60 for Q1 2026.
Revenue beat the consensus estimate of $171.8M by $5.6M. EPS missed the consensus estimate of $0.61 by $0.01.
Compared to the same quarter a year prior, revenue grew 5.0% from $168.9M a year earlier and diluted EPS declined 3.2% from $0.62.
You can read the 8-K earnings release (0001628280-26-028854) and the 10-Q periodic report (0001628280-26-028871) directly on SEC EDGAR. The filing index links above go to sec.gov.